<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798577</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-08-03</org_study_id>
    <nct_id>NCT00798577</nct_id>
  </id_info>
  <brief_title>Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Topical Solutions Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the initial antibiotic effects in the
      treatment of bacterial conjunctivitis symptoms in subjects one year of age and older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exploratory Outcomes From Digital Photography</measure>
    <time_frame>24 hours after administration of first dose</time_frame>
    <description>Photographs were taken before and after treatment. Outcome is the number of patients whose photographs showed a subjective visual change based upon an exploratory review of patient photographs in signs of bacterial conjunctivitis before and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory Evaluation of Changes in Ocular Signs and Symptoms</measure>
    <time_frame>Baseline (Day 1) to Day 2</time_frame>
    <description>Number of patients who had clinical resolution (0 on all scales below) from baseline (Day 1) to Day 2 in ocular and symptoms of bacterial conjunctivitis:
Bulbar Conjunctival Injection - 0 (none) to 4 (Severe) scale. Conjunctival Discharge (Mucopurulent) - 0 (none) to 3 (Severe) scale. Lid Erythema - 0 (none) to 3 (Severe) scale. Lid Swelling - 0 (none) to 3 (Severe) scale. Palpebral Conjunctiva - 0 (none) to 3 (Severe) scale. Foreign Body Sensation - 0 (none) to 3 (Severe) scale. Tearing - 0 (none) to 3 (Severe) scale. Photophobia - 0 (none) to 3 (Severe) scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Culture Evaluation/Eradication Percent - Enterobacter Faecalis and Candida Albicans</measure>
    <time_frame>24 hours after administration of first dose</time_frame>
    <description>Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Culture Evaluation/Eradication Percent - Eradication of All Other Isolates and Corynform-like</measure>
    <time_frame>24 hour after administration of first dose</time_frame>
    <description>Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Culture Evaluation/Eradication Percent - Staphylococcus Aureus, Steptococcus Pneumoniae, and Enterobacter Cloacae</measure>
    <time_frame>24 hours after administration of first dose</time_frame>
    <description>Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Bacterial Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Vigamox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BSS Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Balanced Salt Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigamox Ophthalmic Solution</intervention_name>
    <description>Moxifloxacin 5mg/mL 3 times daily for 7 days</description>
    <arm_group_label>Vigamox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BSS placebo</intervention_name>
    <description>Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days</description>
    <arm_group_label>BSS Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis in one or both eyes of bacterial conjunctivitis based on:

               -  symptoms less than or equal to 24 hours prior to first visit

               -  rating &gt; or equal to 1 for bulbar conjunctival injection

               -  must have a rating &gt; 1 for conjunctival discharge / exudate in at least one eye
                  (the same eye as bulbar conjunctival injection ) at Visit 1, and

          2. Must experience some matting in the affected eye(s).

          3. 1 year of age or older, of any race and either sex

          4. Able to understand and sign an informed consent that has been approved by an
             Institutional Review Board; or if the subject is a minor, the informed consent must be
             signed and understood by the subjects legally authorized representative (parent or
             guardian). Assent to participate should be obtained from subjects 6 years of age or
             older unless not allowed by local regulation.

          5. Must agree to comply with study visit schedule, photographs and other study
             requirements. If subject is a minor, the parent or guardian must agree to ensure
             compliance.

        Exclusion Criteria:

          1. Cannot have had bacterial conjunctivitis as reported by subject (or parent if subject
             is a minor) for &gt; 24 hours.

          2. Any current lid disease on clinical examination.

          3. Known or suspected allergy or hypersensitivity to fluoroquinolones.

          4. Suspected fungal, viral (e.g. Herpes simplex) or Acanthamoeba infection, based on
             clinical observation.

          5. Any systemic or ocular disease or disorder, complicating factors or structural
             abnormality that would negatively affect the conduct or outcome of the study (e.g.,
             hepatitis, acute or chronic renal insufficiency).

          6. Use of topical ocular medications during the study period.

          7. Antibiotics (systemic or topical) may not be used within 7 day of visit 1 or anytime
             after this visit for the duration of the study.

          8. Women of childbearing potential not using reliable means of birth control.

          9. Women who are pregnant or lactating.

         10. Enrollment of more than one person per household at the same time.

         11. Enrollment of the investigator or his or her staff, family members of the
             investigator, family members of the investigator's staff, or individuals living in the
             households of these individuals.

         12. Participation in any investigational drug or device study within 30 days of entering
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Call Center For Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2008</study_first_submitted>
  <study_first_submitted_qc>November 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2008</study_first_posted>
  <results_first_submitted>March 2, 2010</results_first_submitted>
  <results_first_submitted_qc>March 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2010</results_first_posted>
  <last_update_submitted>March 30, 2010</last_update_submitted>
  <last_update_submitted_qc>March 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Paul Cockrum, PhD, Director - Medical Affairs</name_title>
    <organization>Alcon Laboratories, Inc.</organization>
  </responsible_party>
  <keyword>Bacterial Conjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vigamox</title>
          <description>Vigamox Ophthalmic Solution (Moxifloxacin 5 mg/mL) three times daily for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Balanced Salt Solution (BSS) placebo for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vigamox</title>
          <description>Vigamox Ophthalmic Solution (Moxifloxacin 5 mg/mL) three times daily for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Balanced Salt Solution (BSS) placebo for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Outcomes From Digital Photography</title>
        <description>Photographs were taken before and after treatment. Outcome is the number of patients whose photographs showed a subjective visual change based upon an exploratory review of patient photographs in signs of bacterial conjunctivitis before and after treatment.</description>
        <time_frame>24 hours after administration of first dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vigamox</title>
            <description>Vigamox Ophthalmic Solution (Moxifloxacin 5 mg/mL) three times daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Balanced Salt Solution (BSS) placebo for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Outcomes From Digital Photography</title>
          <description>Photographs were taken before and after treatment. Outcome is the number of patients whose photographs showed a subjective visual change based upon an exploratory review of patient photographs in signs of bacterial conjunctivitis before and after treatment.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exploratory Evaluation of Changes in Ocular Signs and Symptoms</title>
        <description>Number of patients who had clinical resolution (0 on all scales below) from baseline (Day 1) to Day 2 in ocular and symptoms of bacterial conjunctivitis:
Bulbar Conjunctival Injection – 0 (none) to 4 (Severe) scale. Conjunctival Discharge (Mucopurulent) - 0 (none) to 3 (Severe) scale. Lid Erythema – 0 (none) to 3 (Severe) scale. Lid Swelling – 0 (none) to 3 (Severe) scale. Palpebral Conjunctiva – 0 (none) to 3 (Severe) scale. Foreign Body Sensation - 0 (none) to 3 (Severe) scale. Tearing - 0 (none) to 3 (Severe) scale. Photophobia - 0 (none) to 3 (Severe) scale.</description>
        <time_frame>Baseline (Day 1) to Day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vigamox</title>
            <description>Vigamox Ophthalmic Solution (Moxifloxacin 5 mg/mL) three times daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Balanced Salt Solution (BSS) placebo for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Evaluation of Changes in Ocular Signs and Symptoms</title>
          <description>Number of patients who had clinical resolution (0 on all scales below) from baseline (Day 1) to Day 2 in ocular and symptoms of bacterial conjunctivitis:
Bulbar Conjunctival Injection – 0 (none) to 4 (Severe) scale. Conjunctival Discharge (Mucopurulent) - 0 (none) to 3 (Severe) scale. Lid Erythema – 0 (none) to 3 (Severe) scale. Lid Swelling – 0 (none) to 3 (Severe) scale. Palpebral Conjunctiva – 0 (none) to 3 (Severe) scale. Foreign Body Sensation - 0 (none) to 3 (Severe) scale. Tearing - 0 (none) to 3 (Severe) scale. Photophobia - 0 (none) to 3 (Severe) scale.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Culture Evaluation/Eradication Percent - Enterobacter Faecalis and Candida Albicans</title>
        <description>Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1</description>
        <time_frame>24 hours after administration of first dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vigamox</title>
            <description>Vigamox Ophthalmic Solution (Moxifloxacin 5 mg/mL) three times daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Balanced Salt Solution (BSS) placebo for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Culture Evaluation/Eradication Percent - Enterobacter Faecalis and Candida Albicans</title>
          <description>Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1</description>
          <units>Percent bacteria eradicated</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Enterobacter faecalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Candida albicans</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Culture Evaluation/Eradication Percent - Eradication of All Other Isolates and Corynform-like</title>
        <description>Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1</description>
        <time_frame>24 hour after administration of first dose</time_frame>
        <population>No patients in the Placebo group had Corynform-like bacteria (or other types of bacteria) identified at Day 1</population>
        <group_list>
          <group group_id="O1">
            <title>Vigamox</title>
            <description>Vigamox Ophthalmic Solution (Moxifloxacin 5 mg/mL) three times daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Balanced Salt Solution (BSS) placebo for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Culture Evaluation/Eradication Percent - Eradication of All Other Isolates and Corynform-like</title>
          <description>Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1</description>
          <population>No patients in the Placebo group had Corynform-like bacteria (or other types of bacteria) identified at Day 1</population>
          <units>Percent bacteria eradicated</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eradication of all other isolates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corynform-like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Culture Evaluation/Eradication Percent - Staphylococcus Aureus, Steptococcus Pneumoniae, and Enterobacter Cloacae</title>
        <description>Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1</description>
        <time_frame>24 hours after administration of first dose</time_frame>
        <population>No patients in the Vigamox group had Staphylococcus aureus, Steptococcus pneumoniae, or Enterobacter cloacae identified at Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Vigamox</title>
            <description>Vigamox Ophthalmic Solution (Moxifloxacin 5 mg/mL) three times daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Balanced Salt Solution (BSS) placebo for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Culture Evaluation/Eradication Percent - Staphylococcus Aureus, Steptococcus Pneumoniae, and Enterobacter Cloacae</title>
          <description>Eradication percent (absence of specified bacteria) of each bacteria identified at Day 1</description>
          <population>No patients in the Vigamox group had Staphylococcus aureus, Steptococcus pneumoniae, or Enterobacter cloacae identified at Day 1.</population>
          <units>Percent bacteria eradicated</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Staphylococcus Aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Steptococcus Pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enterobacter Cloacae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vigamox</title>
          <description>Vigamox Ophthalmic Solution (Moxifloxacin 5 mg/mL) three times daily for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Balanced Salt Solution (BSS) placebo for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All presentations/publications of study results are subject to Alcon approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Labs</organization>
      <phone>1.888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

